The First Drug That Targets Itch Directly, Not Just Atopic Inflammation
For people living with moderate-to-severe atopic dermatitis, itch is rarely just a skin problem. It disrupts sleep, breaks concentration, damages the skin through scratching, and wears down everyday quality of life. Until recently, no approved biologic addressed the itch pathway directly.
That changed with nemolizumab (brand name Nemluvio), developed by Galderma and approved by the FDA for patients aged 12 and older. At the American Academy of Dermatology annual meeting in March 2026 in Denver, late-breaking data from pediatric and long-term studies added new dimensions to what was already a compelling story.
What IL-31 Does, and Why Blocking It Matters
IL-31 is a signaling protein produced by immune cells. What makes it distinctive is that it operates at the intersection of the immune system and the nervous system. It binds to receptors on skin nerve fibers and immune cells simultaneously, triggering itch, weakening the skin barrier, and amplifying inflammation. Think of it as a signal that says “start scratching” while also keeping the inflammatory cycle running.
Most existing atopic dermatitis biologics work by blocking IL-4 and IL-13, two cytokines that drive the inflammatory side of the condition. They do reduce itch indirectly, but they don’t target IL-31 directly. Nemolizumab is a monoclonal antibody (a highly targeted protein engineered to bind one specific molecule) that blocks IL-31 receptor alpha with precision, making it the first of its kind approved for atopic dermatitis.
The ARCADIA Numbers, Translated
The ARCADIA phase III trials enrolled patients 12 and older with moderate-to-severe atopic dermatitis. Results from both ARCADIA 1 and 2:
- IGA success (clear or almost clear skin): 36~38% on nemolizumab vs. 25~26% on placebo, a 10~13 percentage point difference.
- EASI-75 (75% or greater reduction in eczema severity): 42~44% vs. 29~30%.
- Itch relief onset: within 48 hours of the first dose.
The 48-hour itch relief figure stands out. For a condition where itch dominates the patient experience and existing treatments can take weeks to show meaningful improvement, the early onset matters.
Two Years of Data: 90%+ Still Responding
A week-100 interim analysis of patients on continuous treatment showed that over 90% maintained a 4-point improvement in their itch score, and approximately 70% reached a near itch-free state. These are not short-term responders holding on, these are durable results across two years of follow-up.
The AAD 2026 late-breaking session added a pediatric dimension: phase II data in children aged 2~11 showed a similar efficacy profile to adults. Formal pediatric approval has not yet been granted, but the mechanism appears to work consistently across age groups.
Availability and What to Expect
Nemolizumab (Nemluvio) is approved in both the United States and the European Union. The manufacturer is Galderma. Approvals in other markets are pending at different stages.
In the US, the drug requires a prescription and is administered as a subcutaneous injection. List price is approximately $3,500~4,000 per month in the US, with insurance coverage varying significantly. Galderma has patient assistance programs in place, similar to other biologics in the space.
Reported side effects include headache, joint pain (arthralgia), urticaria (hives), and muscle aches (myalgia). Severe immune reactions were infrequent in the trials. If you are currently on an atopic dermatitis treatment regimen or seeing a dermatologist, the most useful question to ask is whether your itch is disproportionate to your visible inflammation, that specific pattern may make IL-31 targeting a particularly relevant option.
Frequently Asked Questions
Who is nemolizumab approved for?
The FDA approved nemolizumab for patients 12 and older with moderate-to-severe atopic dermatitis. Phase II data presented at AAD 2026 showed efficacy in children aged 2-11, with broader approval potentially on the horizon.
How does it compare to dupilumab (Dupixent)?
Dupilumab blocks IL-4 and IL-13, which drive general inflammation. Nemolizumab targets IL-31 receptor alpha, the pathway more specifically responsible for itch and nerve sensitization. The key difference in practice is speed: nemolizumab can reduce itch within 48 hours, versus several weeks for most existing biologics.
What side effects should I know about?
The ARCADIA trials reported headache, joint pain, urticaria (hives), and muscle aches as the main side effects. Severe immune reactions were uncommon, and discontinuation rates were low.